Literature DB >> 6389991

Targeted blood levels of cyclosporin for cardiac transplantation.

B P Griffith, R L Hardesty, A Trento, A Lee, H T Bahnson.   

Abstract

Forty-nine patients have undergone cardiac transplantation since July, 1982, and have been treated with maintenance cyclosporin and low-dose prednisone, 15 to 20 mg. Cyclosporin dose has been targeted to a whole-blood level of 1,000 ng/ml as measured by radioimmune assay. The actuarial survival rate in this group of patients has been 79% at 12 months and 71% at 21 months. Histologic rejection has occurred at all blood levels of cyclosporin, as has significant nephrotoxicity. The hepatic toxicity encountered has been more a clinical nuisance than significant problem. The administered dose of cyclosporin required to reach a target of 1,000 ng/ml has varied between 2 and 30 mg/kg/day. The average perioperative and late serum creatinine levels were 1.2 and 1.49 mg/dl and occurred with cyclosporin levels of 1,078 and 1,068 ng/ml, respectively. Late cyclosporin toxicity has persisted despite reduction in the dose of cyclosporin below the targeted 1,000 ng/ml. Some method of blood level monitoring is necessary in patients receiving cyclosporin immune suppression to assure adequacy of the administered dose. The 1,000 ng/ml target has provided adequate immune suppression. Significant nephrotoxicity has not correlated with the blood level measured.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6389991

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Effect of Chronic Therapy on Absorption and Disposition of Cyclosporine.

Authors:  K Habucky; R Venkataramanan; R J Ptachcinski; G J Burckart; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

2.  Potentiation of vascular smooth muscle cell activity by cyclosporin A.

Authors:  R Locher; R Huss; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Cyclosporin neurotoxicity in cardiac transplant recipients.

Authors:  R J Lane; S W Roche; A A Leung; A Greco; L S Lange
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

4.  Cardiac transplantation. Emerging from an experiment to a service.

Authors:  B P Griffith; R L Hardesty; A Trento; R L Kormos; H T Bahnson
Journal:  Ann Surg       Date:  1986-09       Impact factor: 12.969

5.  Cyclosporin A augments angiotensin II-stimulated rise in intracellular free calcium in vascular smooth muscle cells.

Authors:  J Pfeilschifter; U T Rüegg
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

6.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

Authors:  L M Slater; P Sweet; M Stupecky; S Gupta
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

7.  Synergistic effect of cyclosporin A and verapamil in overcoming vincristine resistance of multidrug-resistant cultured human leukemia cells.

Authors:  Y Ishida; Y Shimada; M Shimoyama
Journal:  Jpn J Cancer Res       Date:  1990-08

8.  Enhancement of reversing effect of cyclosporin A on vincristine resistance by anti-P-glycoprotein monoclonal antibody MRK-16.

Authors:  M Naito; H Tsuge; C Kuroko; A Tomida; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1993-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.